# Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

> **NCT03511365** · PHASE1,PHASE2 · TERMINATED · sponsor: **Northwell Health** · enrollment: 6 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Probiotics MeSH Descriptor Data 2018
- Interleukin-17 MeSH Descriptor Data 2018

## Interventions

- **BIOLOGICAL:** Probiotic Formulation VSL#3

## Key facts

- **NCT ID:** NCT03511365
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-15
- **Primary completion:** 2018-12-14
- **Final completion:** 2019-10-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** IRB haulted the study there was no evidence that the probiotic would benefit the patient
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03511365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03511365, "Effects of Probiotic on Inflammation and Microbiota in Patients With NASH". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT03511365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*